---

Midazolam, Ketamine, and Fentanyl - A Complete Guide

---

Part 1: MIDAZOLAM

Drug Class & Overview

---

Mechanism of Action

Miller's Anesthesia, 10th ed.

---

Pharmacokinetics

• Obesity: High lipophilicity at physiologic pH causes preferential distribution to adipose tissue → prolonged elimination half-life
• Liver cirrhosis: Reduced plasma clearance due to decreased metabolism
• CYP3A4 inhibitors (azole antifungals, HIV protease inhibitors, calcium channel blockers): prolong midazolam half-life significantly
• Renal impairment: Active metabolites accumulate → prolonged sedation (metabolites are normally cleared rapidly in healthy kidneys)
• Neonates/premature infants: Lower clearance; use caution

Miller's Anesthesia, 10th ed.; Goldman-Cecil Medicine

---

Pharmacodynamics

• Reduces cerebral metabolic rate of oxygen (CMRO₂) in a dose-related manner
• Maintains relatively normal CBF:CMRO₂ ratio
• Raises seizure threshold to local anesthetics
• Neuroprotective via prevention of lipid peroxidation and mitochondrial damage
• No intrinsic analgesic activity

• Dose-related respiratory depression: peak effect at 3 minutes, significant depression lasting 60-120 minutes
• Faster administration = faster onset of respiratory depression
• Additive (and potentially synergistic) respiratory depression with opioids, including apnea risk - this is a major clinical safety point
• Unlike propofol, alone it only modestly decreases blood pressure

• Modest blood pressure decrease when used alone
• Significant hypotension when combined with IV opioids - this combination must be given carefully, particularly in hemodynamically compromised patients

• Produces profound anterograde amnesia (cannot form new memories after administration); retrograde memory is relatively preserved
• Impairs both implicit and relational memory - associated with delirium in elderly patients

---

Clinical Uses

---

Contraindications & Cautions

• Known hypersensitivity
• Acute narrow-angle glaucoma
• Pregnancy (crosses placenta)
• Combine with opioids only with close respiratory monitoring
• Paradoxical reactions (restlessness, agitation, disinhibition) can occur

Reversal Agent

---

---

Part 2: KETAMINE

Drug Class & Overview

---

Mechanism of Action

• Primary afferent nociceptors in the spinal dorsal horn
• Inhibitory interneurons in the cortex, limbic system, and hippocampus

---

Pharmacokinetics

---

Pharmacodynamics

• EEG shows depression of thalamocortical pathways + simultaneous activation of the limbic system
• Despite epileptiform activity on EEG, it does not spread to the cortex - ketamine is unlikely to precipitate clinical seizures and may in fact be neuroprotective
• Increases BIS from ~40 to 63 when added to propofol-fentanyl anesthesia (at 0.5 mg/kg)
• Produces lateral gaze nystagmus (characteristic finding)
• Functional MRI: dose-dependent reduction of pain activation along thalamus → insula → cingulate → prefrontal cortex pathway

• Increases heart rate, blood pressure, cardiac output, and SVR
• Mechanism: sympathetic nervous system activation (centrally mediated catecholamine release)
• Important caveat: Ketamine is a direct myocardial depressant. In sympathetically depleted patients (e.g., end-stage shock, catecholamine-exhausted sepsis), the usual sympathomimetic effects cannot mask the direct myocardial depression, leading to cardiovascular collapse
• Increases PVR - caution in severe right heart dysfunction

• Largely maintains spontaneous respiration - a major advantage
• Bronchodilator (relaxes bronchial smooth muscle) - useful in reactive airway disease and status asthmaticus (as adjunct, not sole agent)
• Increases salivation → risk of laryngospasm if airway not protected
• Hypoxia can occur, treated with supplemental O₂

• Historically contraindicated in elevated ICP (due to increased CMRO₂ and CBF)
• Revised view: ICP typically remains normal with ketamine in neurosurgical patients under controlled ventilation; may in fact be neuroprotective
• Associated with epileptiform EEG activity but not clinical seizures

---

Clinical Uses

• Dose: 1-2 mg/kg IV (onset 1 min, duration 10-20 min) or 4-6 mg/kg IM
• Drug of choice in hemodynamically unstable patients
• Advantage over etomidate: does not cause adrenal suppression
• Caution in critical coronary artery disease (tachycardia and increased BP are problematic)

• Particularly useful in pediatrics (fracture reduction, wound care) and burn patients
• Patients maintain open eyes, breathe spontaneously, maintain airway reflexes
• Can be given IM in uncooperative patients

• IV bolus prior to incision + postoperative infusion = most effective regimen
• Reduces postoperative opioid requirements and pain scores
• Analgesic effects at subanesthetic blood concentrations
• Useful in opioid-tolerant patients and those with history of opioid abuse
• Does not fully replace opioids

• CRPS (complex regional pain syndrome) - most extensive evidence
• IV ketamine infusions for refractory chronic pain (expert supervision required)

• IV infusion 0.5 mg/kg over 40 minutes (subanesthetic dose)
• Rapid antidepressant effect within 1 hour; reduces suicidal ideation
• Duration: days to ~2 weeks per single injection
• Mechanism of antidepressant effect: NMDA-independent; involves AMPA receptor activation via metabolite hydroxynorketamine (HNK)
• Intranasal esketamine (Spravato) is FDA-approved for treatment-resistant depression

• Adjunct agent when standard therapy is failing

---

Side Effects

---

---

Part 3: FENTANYL

Drug Class & Overview

---

Mechanism of Action

1. Gi protein is activated → adenylyl cyclase is inhibited → decreased cAMP
2. Potassium channels open → hyperpolarization of the cell
3. Voltage-gated calcium channels close → reduced neurotransmitter release
4. Net effect: decreased neuronal excitability and reduced pain signal transmission

• Spinal cord (dorsal horn): Inhibits release of substance P and glutamate from primary afferent nociceptors → blocks ascending pain transmission
• Supraspinal (PAG, thalamus, limbic system): Activates descending inhibitory pathways
• Peripheral: Direct action on peripheral sensory neurons (important in inflammation)

---

Pharmacokinetics

---

Pharmacodynamics

• Peak analgesic effect after IV administration: ~5 minutes
• Much shorter time to peak effect than morphine (~15 min) or meperidine (~15 min)
• EEG: characteristic δ-wave appearing rapidly after IV injection (t½k₀ ~6.5 min for EEG effect)
• Used intraoperatively to blunt cardiovascular responses to laryngoscopy and surgical stimulation

• Dose-dependent respiratory depression: decreased rate and tidal volume → apnea
• More rapid onset and shorter duration than morphine at standard doses; extended after large doses or long infusions
• "Wooden chest syndrome" (chest wall rigidity): Life-threatening rigidity of the diaphragm, chest wall, and upper airways after rapid IV infusion of large doses. More common in pediatric patients. Treatment: succinylcholine (depolarizing NMB) or nondepolarizing NMB + mechanical ventilation
• Synergistic respiratory depression with benzodiazepines - boxed warning on both drug classes

• Decreases heart rate via vagal activation (bradycardia)
• Modestly decreases blood pressure
• Does not release histamine → minimal direct myocardial depressant effect
• Excellent hemodynamic stability - this is why high-dose fentanyl (5-75 mcg/kg) is used as the primary anesthetic in cardiac surgery and patients with poor cardiac function

• Delayed gastric emptying
• Nausea and vomiting
• Constipation (no tolerance develops to this effect)
• Pruritus (especially with neuraxial administration)
• Urinary retention

• Repeated use produces tolerance to: respiratory depression, analgesia, euphoria, emesis, sedation
• Tolerance does not typically develop to: miosis and constipation
• Physical and psychological dependence can occur; abrupt discontinuation causes withdrawal

---

Clinical Uses

• Bolus doses of 1-3 mcg/kg during induction; repeated 25-100 mcg boluses intraoperatively
• Blunts hemodynamic responses to laryngoscopy and surgical stimulation
• C₅₀ for analgesia = 1-2 ng/mL; C₅₀ for hemodynamic responses = higher

• 5-75 mcg/kg - achieves plasma concentrations of 10-30 ng/mL
• Provides analgesia + hemodynamic stability without significant myocardial depression
• Historical technique: fentanyl + N₂O; now superseded by TIVA (total IV anesthesia) or balanced anesthesia with propofol + fentanyl

• Transdermal fentanyl patch: 12-100 mcg/h; peak analgesic effect only after 10-12 hours; one patch lasts 3-4 days; absorption varies by skin thickness, subcutaneous fat, and perfusion
• Intranasal, sublingual, lozenge ("lollipop"), mucosal patch - all for breakthrough pain
• Iontophoretic transdermal system

• Commonly combined with midazolam for procedural sedation
• The combination produces synergistic CNS and respiratory depression - requires close monitoring

• Widely used for labor analgesia, postoperative pain
• Can cause pruritus (treated with low-dose naloxone or nalbuphine)

---

Routes of Administration Summary

---

Reversal Agent

---

---

Part 4: COMPARATIVE SUMMARY TABLE

---

Part 5: COMBINATION USE - THE "KETOFOL" & "MIDAZOLAM + FENTANYL" PRINCIPLES

• The most common procedural sedation combination for GI endoscopy, minor procedures
• Synergistic CNS and additive-to-synergistic respiratory depression - the most dangerous aspect
• A boxed warning on both drug classes warns against co-prescribing
• Midazolam alone does not provide "reliable sedation for procedures" - the combination is required

• Benzodiazepine co-administration significantly reduces ketamine's emergence delirium, hallucinations, and psychotomimetic effects
• Midazolam (1-2 mg IV prior to ketamine) is standard practice for adult procedural sedation with ketamine

• Ketamine reduces postoperative opioid requirements and prevents opioid-induced hyperalgesia
• Note: the midazolam-fentanyl antinociceptive interaction is reported to be less than additive (at least in animal models), while ketamine + opioid combinations tend to be at least additive or synergistic for analgesia

---

Part 6: SAFETY - CRITICAL POINTS

1. Opioid + benzodiazepine combination (FDA Boxed Warning): Fentanyl and midazolam together produce synergistic respiratory depression - both drugs carry black box warnings against co-prescribing outside monitored settings
2. Ketamine in catecholamine-depleted patients: The drug is a direct myocardial depressant; sympathomimetic effects mask this in most patients. In severely depleted patients (prolonged hemorrhagic shock, end-stage sepsis), cardiovascular collapse can occur.
3. Fentanyl accumulation: A single small bolus wears off quickly (redistribution); prolonged infusions saturate peripheral compartments and fentanyl becomes very long-acting. Always account for context-sensitive half-time.
4. Wooden chest syndrome with fentanyl: Rapid IV injection of large doses → chest wall rigidity → unable to ventilate. Treat with succinylcholine + intubation. More common in neonates/pediatric patients.
5. Midazolam in renal impairment: Active metabolites (1-OH-midazolam) accumulate → unexpectedly prolonged sedation.
6. Reversal agents do not eliminate the drug - they compete at the receptor. Naloxone (t½ ~60-90 min) wears off before fentanyl in overdose. Flumazenil wears off before midazolam. Monitor for re-sedation.

---

• Miller's Anesthesia, 10th ed. (Elsevier, 2023) - Chapters 21, 32
• Barash, Cullen & Stoelting's Clinical Anesthesia, 9th ed. - Chapters 19, 20
• Goodman & Gilman's The Pharmacological Basis of Therapeutics - Chapter 7
• Goldman-Cecil Medicine, International Ed. - Chapter 58
• Lippincott Illustrated Reviews: Pharmacology - Chapter 21

Recent Evidence Note: A 2026 systematic review and meta-analysis (PMID: 41698174) on procedural sedation in emergency departments confirms the high efficacy of these agents while noting adverse outcome profiles consistent with the above.That covers everything from first principles through advanced clinical application. Here's a quick orientation to what was covered:

---